1-3-2023

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

Brandon M Huffman
Atrayee Basu Mallick
Nora K Horick
Andrea Wang-Gillam
Peter Joel Hosein

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/medoncfp

Part of the Oncology Commons

Let us know how access to this document benefits you

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Brandon M Huffman, Atrayee Basu Mallick, Nora K Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A Morse, Muhammad Shaalan Beg, Janet E Murphy, Sharon Mavroutakis, Anjum Zaki, Benjamin L Schlechter, Hanna Sanoff, Christopher Manz, Brian M Wolpin, Philip Arlen, Jill Lacy, and James M Cleary
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
A Randomized Clinical Trial

Brandon M. Huffman, MD; Atrayee Basu Mallick, MD; Nora K. Horick, MS; Andrea Wang-Gillam, MD; Peter Joel Hosein, MD; Michael A. Morse, MD; Muhammad Shaalan Beg, MD; Janet E. Murphy, MD, MPH; Sharon Mavroukakis, RN, MS; Anjum Zaki; Benjamin L. Schlechter, MD; Hanna Sanoff, MD, MPH; Christopher Manz, MD; Brian M. Wolpin, MD, MPH; Philip Arlen, MD; Jill Lacy, MD; James M. Cleary, MD, PhD

Abstract

IMPORTANCE Treatment options are limited for patients with advanced pancreatic ductal adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), with such individuals commonly being treated with gemcitabine and nab-paclitaxel.

OBJECTIVE To determine whether NPC-1C, an antibody directed against MUC5AC, might increase the efficacy of second-line gemcitabine and nab-paclitaxel in patients with advanced PDAC.

DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized phase II clinical trial enrolled patients with advanced PDAC between April 2014 and March 2017 whose disease had progressed on first-line FOLFIRINOX. Eligible patients had tumors with at least 20 MUC5AC staining by centralized immunohistochemistry review. Statistical analysis was performed from April to May 2022.

INTERVENTIONS Patients were randomly assigned to receive gemcitabine (1000 mg/m²) and nab-paclitaxel (125 mg/m²) administered intravenously on days 1, 8, and 15 of every 4-week cycle, with or without intravenous NPC-1C 1.5 mg/kg every 2 weeks.

MAIN OUTCOMES AND MEASURES The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS), objective response rate (ORR), and safety. Pretreatment clinical variables were explored with Cox proportional hazards analysis.

RESULTS A total of 78 patients (median [range] age, 62 [36-78] years; 32 [41%] women; 9 [12%] Black; 66 [85%] White) received second-line treatment with gemcitabine plus nab-paclitaxel (n = 40) or gemcitabine plus nab-paclitaxel and NPC-1C (n = 38). Median OS was 6.6 months (95% CI, 4.7-8.4 months) with gemcitabine plus nab-paclitaxel vs 5.0 months (95% CI, 3.3-6.5 months; P = .22) with gemcitabine plus nab-paclitaxel and NPC-1C. Median PFS was 2.7 months (95% CI, 1.9-4.1 months) with gemcitabine plus nab-paclitaxel vs 3.4 months (95% CI, 1.9-5.3 months; P = .80) with gemcitabine plus nab-paclitaxel and NPC-1C. The ORR was 3.1% (95% CI, 0.4%-19.7%) in the gemcitabine plus nab-paclitaxel and NPC-1C group and 2.9% (95% CI, 0.4%-18.7%) in the gemcitabine plus nab-paclitaxel group. No differences in toxicity were observed between groups, except that grade 3 or greater anemia occurred more frequently in patients treated with gemcitabine plus nab-paclitaxel and NPC-1C than gemcitabine plus nab-paclitaxel (39% [15 of 38] vs 10% [4 of 40]; P = .003). The frequency of chemotherapy dose reductions was similar in both groups (65% vs 74%; P = .47). Lower performance status, hypoalbuminemia, PDAC diagnosis less than or equal to (continued)

Key Points

Question Does targeting MUC5AC with the NPC-1C antibody augment the antitumor activity of gemcitabine plus nab-paclitaxel as a second-line treatment for pancreatic cancer?

Findings In this randomized phase 2 trial of 78 patients with advanced pancreatic cancer who previously progressed on first-line FOLFIRINOX, the addition of NPC-1C to second-line gemcitabine plus nab-paclitaxel did not prolong overall survival.

Meaning Although NPC-1C did not enhance the efficacy of gemcitabine plus nab-paclitaxel in second-line advanced pancreatic cancer, this study establishes efficacy benchmarks, dose modification patterns, and characteristics associated with survival among patients receiving second-line gemcitabine plus nab-paclitaxel.
Abstract (continued)

18 months before trial enrollment, lymphocyte-to-monocyte ratio less than 2.8, and CA19-9 greater than 2000 IU/mL were independently associated with poorer survival.

CONCLUSIONS AND RELEVANCE In this randomized clinical trial of advanced PDAC, NPC-1C did not enhance the efficacy of gemcitabine/nab-paclitaxel. These data provide a benchmark for future trials investigating second-line treatment of PDAC.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01834235

Introduction

The aggressive biology of advanced pancreatic adenocarcinoma (PDAC), along with its limited sensitivity to cytotoxic chemotherapy, make systemic therapy for patients with advanced PDAC an enormous management challenge. Treatment options are limited and typically consist of 2 cytotoxic chemotherapy regimens that have modest efficacy. First-line chemotherapy options for patients with metastatic PDAC who have a good performance status are FOLFIRINOX (fluororuracil, leucovorin, irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel. After progression on first-line therapy, patients initially treated with gemcitabine plus nab-paclitaxel are usually offered a fluororuracil-based regimen, whereas patients initially treated with FOLFIRINOX are commonly treated with second-line gemcitabine plus nab-paclitaxel. Although clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) endorse second-line gemcitabine plus nab-paclitaxel, this recommendation is based on data obtained in the first-line setting, and there are limited prospective data evaluating the efficacy and tolerability of gemcitabine plus nab-paclitaxel in the second-line setting. This paucity of data poses a challenge for clinicians deciding on the appropriate dosing regimen for their patients and for investigators who need efficacy benchmarks for second-line studies involving gemcitabine plus nab-paclitaxel.

The therapeutic strategy of combining cytotoxic chemotherapy with immunogenic antibodies directed against cell-surface proteins has been successful in many malignant neoplasms, and identification of cell-surface targets for this purpose in the setting of pancreatic cancer is of great interest. The NPC-1C (NEO-102; ensituximab) chimeric IgG1 monoclonal antibody binds a cell-surface antigen found in an allogeneic tumor associated antigen (TAA)–based vaccine that showed preliminary signs of clinical efficacy against colorectal adenocarcinoma. NPC-1C targets an aberrantly glycosylated mucin, MUC5AC, which is produced by pancreatic and colorectal adenocarcinomas, but not by normal tissue. Preclinical analysis has revealed that exposure to NPC-1C induces antibody-dependent cellular cytotoxicity (ADCC) in MUC5AC-positive PDAC cell lines. MUC5AC plays a role in PDAC progression by enhancing its desmoplastic reaction and promoting metastatic spread. In an autochthonous mouse model of PDAC, MUC5AC deficiency impairs oncogenic progression of PDAC precursor lesions and decreases tumor formation. Similarly, treatment of murine PDAC models with NPC-1C delays PDAC tumor growth.

A phase I clinical trial of NPC-1C monotherapy demonstrated a favorable toxicity profile with anemia being the most common grade 3 or 4 toxic effect. In an unpublished cohort of 5 patients with advanced PDAC, NPC-1C combined with gemcitabine was well-tolerated with no unexpected toxic effects. Notably, NPC-1C monotherapy showed encouraging signs of disease control as a single agent in colorectal cancer and PDAC patients with 31% having disease control at 8 weeks. We hypothesized that NPC-1C would enhance the activity of second-line gemcitabine plus nab-paclitaxel in patients with advanced PDAC. Here, we report the results of a randomized phase II trial evaluating...
the efficacy of second-line gemcitabine plus nab-paclitaxel and NPC-1C vs gemcitabine plus nab-paclitaxel alone in patients with advanced PDAC.

Methods

Trial Design
This multi-institutional, open-label, randomized phase II clinical trial was approved by each site's institutional review board and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines (Supplement 1). Thirteen clinical centers in the United States participated in the study. All participants provided written informed consent before participation. The study was registered at ClinicalTrials.gov (NCT01834235) and followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline for randomized clinical trials. The study was industry-sponsored. The manuscript was written by the academic investigators and approved by the sponsor.

Study Population
Eligible patients had pathologically confirmed, locally advanced unresectable, or metastatic PDAC that progressed after primary therapy with FOLFIRINOX, a FOLFIRINOX-like regimen, or were intolerant of it. A FOLFIRINOX–like regimen was defined as fluororuracil/leucovorin or capecitabine combined with irinotecan, oxaliplatin, or both agents. Patients were eligible if their tumor stained with the NPC-1C antibody by at least 20% (tumor staining score) as determined by centralized immunohistochemical review. Patients needed to be at least 18 years of age, have measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, and have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Key exclusion criteria included prior receipt of second-line therapy, known brain metastases, any major surgery within 4 weeks of enrollment, and higher than grade 2 ascites at the time of enrollment. Basic demographics, including self-reported race and ethnicity, were prospectively collected for each patient to determine generalizability.

Patients were randomized in a 1:1 ratio to groups receiving gemcitabine plus nab-paclitaxel combined with NPC-1C or gemcitabine plus nab-paclitaxel alone (eFigure 1 in Supplement 2). The randomization was generated by the Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute.

Treatment Protocols
All patients initially received gemcitabine (1000 mg/m²) and nab-paclitaxel (125 mg/m²) administered intravenously (IV) on days 1, 8, and 15 of each 28-day cycle. Patients randomized to the experimental group also received NPC-1C (1.5 mg/kg) IV on days 1 and 15. Protocol therapy continued until disease progression, unacceptable toxic effects, or withdrawal of consent. Modifications of the dosing schedules of gemcitabine plus nab-paclitaxel were made at the investigators' discretion and in accordance with the US Food and Drug Administration label. Two dose reductions of gemcitabine and nab-paclitaxel were allowed. Gemcitabine was reduced from 1000 mg/m² to 800 mg/m² and 600 mg/m² while nab-paclitaxel was reduced from 125 mg/m² to 100 mg/m² and 75 mg/m². When patients experienced toxic effects, investigators could elect to alter the gemcitabine plus nab-paclitaxel administration schedule or discontinue either gemcitabine or nab-paclitaxel. A schedule modification was defined as any time, regardless of the reason, that a patient did not receive an assigned administration of chemotherapy within a cycle.

Efficacy and Safety Assessments
The primary end point was overall survival (OS), defined as the time from start of treatment to death from any cause. Secondary end points were objective response rate (ORR), disease control rate, progression-free survival (PFS), and safety. PFS was defined as the time from treatment start to...
cancer progression or death, whichever occurred first. The ORR was determined according to RECIST version 1.1, and the disease control rate was defined as having at least a radiographic partial response or stable disease greater than or equal to 16 weeks. Radiological assessments occurred every 8 weeks. Adverse reactions were evaluated according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. Following enrollment of the first 6 patients on the experimental group, a protocol-mandated halt to enrollment occurred so the safety of gemcitabine plus nab-paclitaxel and NPC-1C could be assessed.

Statistical Analysis
A sample size of 90 patients enabled the trial to have 80% power, at a 1-sided 10% significance level, to detect an increase in median OS from an anticipated 5 months in the gemcitabine plus nab-paclitaxel group to 8 months in the gemcitabine plus nab-paclitaxel and NPC-1C group. A log-rank test was applied to evaluate differences in PFS and OS between groups. The Kaplan-Meier method was used to assess PFS and OS with 95% CIs. A 2-sided \( P < .05 \) was considered statistically significant. Hazard ratios (HRs) indicating the treatment effect on OS within subgroups according to baseline characteristics were calculated and displayed in a forest plot. Differences in the treatment effect between subgroups were evaluated via interaction terms in Cox proportional hazards models.

A post hoc analysis was performed to examine whether any baseline or disease characteristics were associated with OS in univariate and multivariate analyses. We used traditional clinical and demographic factors including number of metastatic sites, pretreatment serum albumin level, performance status, curative-intent therapy with radiation and/or surgery, time from diagnosis to trial enrollment, and sites of metastatic disease. In addition, we used serological biomarkers of immune activation, such as an elevated neutrophil-to-lymphocyte ratio and decreased lymphocyte-to-monocyte ratio, that may have prognostic value in multiple malignant neoplasms, including pancreatic cancer. The neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio were calculated with cell counts obtained in the pretreatment complete blood count (CBC). The multivariable Cox proportional hazards regression model included forced variables (treatment group, age, sex, stage at trial entry, and performance status) and all optional clinical factors with \( P < .2 \) in univariate analysis with OS. Backward selection was used to remove optional clinical factors with \( P > .05 \) in the multivariable model. All analyses were performed in Stata version 17 (StataCorp), SAS version 9.4 (SAS Institute), or R version 4.0.3 (R Project for Statistical Computing).

Results
The baseline demographic and clinical characteristics are described in Table 1. Between April 2014 and March 2017, 230 patients were screened for eligibility. As part of eligibility prescreening, an immunohistochemical analysis was performed on archival tumor samples, and 130 patients (56.5%) met the eligibility criteria of having tumors with at least 20% of cells that bound NPC-1C. Eighty patients enrolled in the trial and were randomly assigned to gemcitabine plus nab-paclitaxel and NPC-1C (39 patients) or gemcitabine plus nab-paclitaxel (41 patients). One patient from each group withdrew or became ineligible for the trial before receiving therapy, so they were excluded from subsequent analyses (eFigure 1 in Supplement 2). Among the 78 treated patients (median [range] age, 62 [36-78] years; 32 [41%] women; 9 [12%] Black; 66 [85%] White), 35 patients (45%) had 20% to 40% of cells with positive NPC-1C tumor staining, 17 (22%) had 41% to 60% NPC-1C tumor staining, and 26 (33%) had 61% to 100% NPC-1C tumor staining (eTable 1 in Supplement 2).

The baseline demographic and disease characteristics were reasonably balanced between treatment groups (Table 1). Locally advanced disease was rare in both groups (3% in gemcitabine plus nab-paclitaxel and NPC-1C group vs 8% in gemcitabine plus nab-paclitaxel alone group). The median (range) time from initial diagnosis was 12.3 (0.6-58) months. The gemcitabine plus nab-paclitaxel and...
NPC-1C group had fewer women and patients with peripheral neuropathy than the gemcitabine plus nab-paclitaxel group.

As of the data cutoff on September 30, 2019, all patients had discontinued study treatment or died. The most common reason for removal from the trial was progressive disease in patients.

### Table 1. Baseline Characteristics of Patients Who Started Protocol Treatment

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
<th>Gemcitabine/nab-paclitaxel/NPC-1C (n = 38)</th>
<th>Gemcitabine/nab-paclitaxel (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), y</td>
<td>59 (36-78)</td>
<td>63 (37-78)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>11 (29)</td>
<td>21 (52)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>27 (71)</td>
<td>19 (48)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>5 (13)</td>
<td>4 (10)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>32 (84)</td>
<td>34 (85)</td>
<td></td>
</tr>
<tr>
<td>Othera</td>
<td>1 (3)</td>
<td>2 (5)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>4 (11)</td>
<td>4 (10)</td>
<td></td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>33 (87)</td>
<td>34 (85)</td>
<td></td>
</tr>
<tr>
<td>Otherb</td>
<td>1 (3)</td>
<td>2 (5)</td>
<td></td>
</tr>
<tr>
<td>Time from initial diagnosis, median (range), mo</td>
<td>11.6 (2-58)</td>
<td>12.6 (0.6-46)</td>
<td></td>
</tr>
<tr>
<td>Performance status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG 0</td>
<td>12 (32)</td>
<td>15 (38)</td>
<td></td>
</tr>
<tr>
<td>ECOG 1</td>
<td>26 (68)</td>
<td>25 (62)</td>
<td></td>
</tr>
<tr>
<td>NPC-1C staining, median (range)</td>
<td>50 (20-100)</td>
<td>60 (20-100)</td>
<td></td>
</tr>
<tr>
<td>Baseline neuropathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>12 (32)</td>
<td>23 (58)</td>
<td></td>
</tr>
<tr>
<td>Baseline diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>12 (32)</td>
<td>11 (28)</td>
<td></td>
</tr>
<tr>
<td>Stage at trial entry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Locally advanced</td>
<td>1 (3)</td>
<td>3 (8)</td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>37 (97)</td>
<td>37 (92)</td>
<td></td>
</tr>
<tr>
<td>Metastatic sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenal</td>
<td>1 (3)</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>3 (8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>30 (79)</td>
<td>28 (70)</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>7 (18)</td>
<td>8 (20)</td>
<td></td>
</tr>
<tr>
<td>Lymph node</td>
<td>8 (21)</td>
<td>9 (23)</td>
<td></td>
</tr>
<tr>
<td>Peritoneal</td>
<td>7 (18)</td>
<td>11 (28)</td>
<td></td>
</tr>
<tr>
<td>CA19-9 level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range), IU/mL</td>
<td>2483, (0-678 278)</td>
<td>1547, (0-45 842)</td>
<td></td>
</tr>
<tr>
<td>(&lt;17 IU/mL) Normal</td>
<td>7 (18)</td>
<td>4 (10)</td>
<td></td>
</tr>
<tr>
<td>ULN&lt;59 x ULN</td>
<td>11 (29)</td>
<td>20 (50)</td>
<td></td>
</tr>
<tr>
<td>≥59 x ULN (N, %)</td>
<td>20 (53)</td>
<td>16 (40)</td>
<td></td>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, range</td>
<td>3.8 (2.4-4.5)</td>
<td>3.9 (2.8-4.8)</td>
<td></td>
</tr>
<tr>
<td>≥3.4 g/dL</td>
<td>30 (79)</td>
<td>36 (90)</td>
<td></td>
</tr>
<tr>
<td>&lt;3.4 g/dL</td>
<td>8 (21)</td>
<td>4 (10)</td>
<td></td>
</tr>
<tr>
<td>Prior therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>38 (100)</td>
<td>40 (100)</td>
<td></td>
</tr>
<tr>
<td>Pancreatic surgery</td>
<td>7 (18)</td>
<td>13 (33)</td>
<td></td>
</tr>
<tr>
<td>Radiation</td>
<td>8 (21)</td>
<td>10 (25)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ECOG, Eastern Cooperative Oncology Group; g/dL, grams/deciliter; IU/mL, International Units/milliliter; ULN, upper limit of normal.

* Other races were reported as "unknown."

* Other ethnicities were reported as "unknown."

SI conversion factor: To convert albumin levels to g/L, multiply by 10.
receiving gemcitabine plus nab-paclitaxel and NPC-1C or gemcitabine plus nab-paclitaxel (68% vs 58%, \( P = .49 \)). The median (range) treatment duration was 2.3 (0.4-8.4) months for the gemcitabine plus nab-paclitaxel group and 2.7 (0.3-16.5) months for the gemcitabine plus nab-paclitaxel and NPC-1C group (\( P = .53 \)).

Efficacy

A preplanned interim futility analysis determined there was no benefit to combining NPC-1C with gemcitabine and nab-paclitaxel, and the trial was closed early (after 80 patients had enrolled) by the Data and Safety Monitoring Committee because of a lack of efficacy. The trial did not meet its primary end point as the addition of NPC-1C to gemcitabine plus nab-paclitaxel did not prolong OS. The median OS was 5.0 months (95% CI, 3.3-6.5 months) for patients in the gemcitabine plus nab-paclitaxel and NPC-1C group and 6.6 months (95% CI, 4.7-8.4 months) for those in the gemcitabine plus nab-paclitaxel group (log-rank \( P = .53 \)) (Figure 1A). The OS rates were 48.7% (95% CI, 32%-63.5%) for 6 months and 15.8% (95% CI, 6.2%-29.4%) for 12 months for the gemcitabine plus nab-paclitaxel and NPC-1C group vs 53.0% (95% CI, 36.2%-67.3%) for 6 months and 21.2% (95% CI, 10.0%-35.2%) for 12 months for the gemcitabine plus nab-paclitaxel group.

The median PFS was 3.5 months (95% CI, 2.0-5.6 months) for the gemcitabine plus nab-paclitaxel and NPC-1C group and 2.7 months (95% CI, 1.9-4.1 months) for the gemcitabine plus nab-paclitaxel group (log-rank \( P = .80 \)). The HR for progression after gemcitabine plus nab-paclitaxel and NPC-1C vs gemcitabine plus nab-paclitaxel was 1.04 (95% CI, 0.67-1.69; \( P = .80 \)) (Figure 1B). The PFS was 32.5% (95% CI, 18.3%-47.6%) for 6 months and 8.1% (95% CI, 2.1%-19.6%) for 12 months for the gemcitabine plus nab-paclitaxel and NPC-1C group vs 24.2% (95% CI, 12.1%-38.6%) for 6 months and 13.5% (95% CI, 4.9%-26.3%) for 12 months for the gemcitabine plus nab-paclitaxel group.

Similarly, no significant difference in ORR was observed between groups (n = 66 evaluable patients). One patient in each group had a confirmed objective response. The ORR was 3.1% (95% CI, 0.4%-19.7%) in the gemcitabine plus nab-paclitaxel and NPC-1C group (n = 32) and 2.9% (95% CI, 0.4%-18.7%) in the gemcitabine plus nab-paclitaxel group (n = 34) (eTable 2 in Supplement 2). There was also no difference in the disease control rate, defined as having at least a radiographic partial response or stable disease greater than or equal to 16 weeks, between the 2 treatment groups. The disease control rate was 28.1% (95% CI, 15.1%-46.2%) in the gemcitabine plus nab-paclitaxel and
NPC-1C group and 23.5% (95% CI, 12.1%-40.8%) in the gemcitabine plus nab-paclitaxel group ($P = .78$).

A post hoc subgroup analysis examining multiple demographic and baseline disease characteristics, including age, ECOG performance status, staging, number of sites of metastases, and NPC-1C staining score, did not identify any subgroup of patients with significantly prolonged OS among patients treated with gemcitabine plus nab-paclitaxel and NPC-1C compared with patients treated with gemcitabine plus nab-paclitaxel alone (eFigure 2 in Supplement 2).

**Safety**

The most common grade 3 or 4 adverse events observed were toxic effects typically reported for gemcitabine plus nab-paclitaxel: myelosuppression, fatigue, liver function test abnormalities, and neuropathy (Table 2; and eTable 3 and 4 in Supplement 2). Treatment-associated grade 3 or 4 anemia was observed more frequently in patients receiving gemcitabine plus nab-paclitaxel and NPC-1C (39%) than in those in the gemcitabine/nab-paclitaxel group (39% [15/38] vs 10% [4/40]; $P = .003$) (Table 2). No other significant differences in toxic effects were observed between treatment groups (eTable 4 in Supplement 2). Adverse events resulted in the discontinuation of protocol therapy in 7.9% (95% CI, 2.5%-22.5%) of patients receiving gemcitabine plus nab-paclitaxel and NPC-1C and 17.5% (95% CI, 8.4%-33.0%) of patients receiving gemcitabine plus nab-paclitaxel ($P = .31$). Notably, no treatment-associated grade 5 events occurred in either group.

**Dose and Treatment Schedule Modifications**

Dose modifications of gemcitabine plus nab-paclitaxel were common in both groups, and no differences were observed in the frequency of dose or schedule modifications in either group (eTable 5 in Supplement 2). Chemotherapy dose reductions occurred at least once during the treatment course in 28 of the 38 patients (74%) receiving gemcitabine plus nab-paclitaxel and NPC-1C and 26 of the 40 patients (65%) receiving gemcitabine plus nab-paclitaxel ($P = .47$) (eTable 6 in Supplement 2). Chemotherapy schedule modifications occurred at least once during the treatment course in 29 of the 38 patients (76%) in gemcitabine plus nab-paclitaxel and NPC-1C group and 26 of the 40 patients (65%) in the gemcitabine plus nab-paclitaxel group ($P = .33$) (eTable 7 in Supplement 2). By the end of cycle 1, 30 of 38 patients (78.9%) receiving gemcitabine plus nab-paclitaxel and NPC-1C and 25 of 40 patients (62.5%) receiving gemcitabine plus nab-paclitaxel had undergone either a dose reduction or schedule modification ($P = .14$). Chemotherapy dose reductions in cycle 1 occurred in 20 of 38 patients (52.6%) receiving gemcitabine plus nab-paclitaxel and NPC-1C and 16 of 40 patients (40.0%) on gemcitabine plus nab-paclitaxel ($P = .33$) (eTable 6 in Supplement 2). Schedule modifications during cycle 1 occurred in 20 of 38 patients (52.6%) receiving gemcitabine plus nab-paclitaxel and NPC-1C and 14 of 40 patients (35.0%) on gemcitabine plus nab-paclitaxel ($P = .03$) (eTable 7 in Supplement 2).

### Table 2. Most Common Grade 3 or 4 Adverse Events Possibly, Probably, or Definitely Associated With Protocol Treatment

<table>
<thead>
<tr>
<th>Grade ≥3 events</th>
<th>No. (%)</th>
<th>Gemcitabine/ nab-paclitaxel/NPC-1C (n = 38)</th>
<th>Gemcitabine/ nab-paclitaxel (n = 40)</th>
<th>$P$ value$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>19 (24)</td>
<td>15 (39)</td>
<td>4 (10)</td>
<td>.003</td>
</tr>
<tr>
<td>Anemia</td>
<td>6 (8)</td>
<td>5 (13)</td>
<td>1 (3)</td>
<td>.10</td>
</tr>
<tr>
<td>Fatigue</td>
<td>8 (10)</td>
<td>6 (16)</td>
<td>2 (5)</td>
<td>.15</td>
</tr>
<tr>
<td>Liver function test$^b$</td>
<td>6 (8)</td>
<td>3 (8)</td>
<td>3 (8)</td>
<td>&gt;.99</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>26 (33)</td>
<td>14 (37)</td>
<td>12 (30)</td>
<td>.63</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>4 (5)</td>
<td>3 (8)</td>
<td>3 (8)</td>
<td>.62</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>20 (26)</td>
<td>12 (32)</td>
<td>8 (20)</td>
<td>.30</td>
</tr>
</tbody>
</table>

$^a$ $P$ value comparing gemcitabine plus nab-paclitaxel and NPC-1C vs gemcitabine plus nab-paclitaxel.

$^b$ Liver function test defined as an abnormality in aspartate transaminase, alanine transaminase, or total bilirubin.
In an exploratory analysis, we combined the patients in both groups to understand how clinicians adjust therapy in advanced cycles. In the third cycle, 31 of the 38 patients (81.6%) remaining in the trial had undergone a chemotherapy dose reduction (52.6% [20 of 38]) and/or schedule modification (57.9% [22 of 38]). Of those patients, 14 (37%) received full dose gemcitabine plus nab-paclitaxel, 10 (26%) received gemcitabine 800 mg/m² and/or nab-paclitaxel 100 mg/m², and 14 (37%) received doses below either gemcitabine 800 mg/m² or nab-paclitaxel 100 mg/m². Additionally, in cycle 3, 8 patients (21%) received chemotherapy every other week, and 9 patients (24%) received chemotherapy for 2 weeks on followed by 2 weeks off.

Clinical Features Associated With Survival

Given the limited data on factors associated with survival for patients with advanced PDAC treated with second-line gemcitabine plus nab-paclitaxel, we performed a post hoc analysis to examine whether any baseline clinical or demographic factors were associated with OS. Because we observed no statistically significant differences in efficacy outcomes in both groups, to increase statistical power, our analysis included all patients treated in the trial. Albumin less than 3.4 g/dL (to convert to grams per liter, multiply by 10), diabetes, presence of liver metastases, 2 or more metastatic sites of disease, lymphocyte-to-monocyte ratio less than 2.8, neutrophil-to-lymphocyte ratio greater than 5, platelet-to-lymphocyte ratio at least 180, PDAC diagnosis less than or equal to 18 months before trial enrollment, surgery and/or radiation, neuropathy, and CA19-9 greater than 2000 IU/mL were included in the initial multivariable model based on the results of the univariate analysis (eTable 8 in Supplement 2). In the final multivariable analysis model, lower performance status (HR, 3.92; 95% CI, 1.51-10.13; P = .005), albumin less than 3.4 g/dL (HR, 2.94; 95% CI, 1.15-7.52; P = .02), lymphocyte-to-monocyte ratio less than 2.8 (HR, 3.83; 95% CI, 1.57-9.30; P = .003), PDAC diagnosis less than or equal to 18 months before trial enrollment (HR, 2.77; 95% CI, 1.30-5.88; P = .008), and CA19-9 greater than 2000 IU/mL (HR, 3.38; 95% CI, 1.46-7.81; P = .004) were independently associated with OS (Table 3).

Having identified clinical and demographic factors that were associated with prognosis, we next examined the prognosis associated with these factors among patients with multiple high-risk features. The median OS was 8.0 months (95% CI, 6.0-12.0 months) for patients with 2 or fewer factors but only 4.3 months (95% CI, 2.6-5.6 months; P < .001) for patients with 3 to 5 factors (Figure 2; eFigure 3 in Supplement 2).

Discussion

Gemcitabine plus nab-paclitaxel is commonly used as second-line therapy in patients with PDAC who have previously been treated with first-line FOLFIRINOX. This randomized clinical trial found that the addition of NPC-1C, an anti-MUC5AC monoclonal antibody, to second-line gemcitabine plus

Table 3. Multivariable Analysis Model of Features Associated With Overall Survival

<table>
<thead>
<tr>
<th>Baseline characteristic</th>
<th>Reference</th>
<th>Comparator</th>
<th>Hazard ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>&lt;50</td>
<td>≥50</td>
<td>0.51 (0.17-1.49)</td>
<td>.22</td>
</tr>
<tr>
<td>Albumin &lt;3.4 g/dL</td>
<td>No</td>
<td>Yes</td>
<td>2.94 (1.15-7.52)</td>
<td>.02</td>
</tr>
<tr>
<td>CA19-9 &gt; 2000 IU/mL</td>
<td>No</td>
<td>Yes</td>
<td>3.38 (1.46-7.81)</td>
<td>.004</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>0</td>
<td>1</td>
<td>3.92 (1.51-10.13)</td>
<td>.005</td>
</tr>
<tr>
<td>Lymphocyte-to-monocyte ratio &lt;2.8</td>
<td>No</td>
<td>Yes</td>
<td>3.83 (1.57-9.30)</td>
<td>.003</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Female</td>
<td>1.64 (0.78-3.44)</td>
<td>.19</td>
</tr>
<tr>
<td>Stage</td>
<td>Locally advanced</td>
<td>Metastatic</td>
<td>1.29 (0.40-4.14)</td>
<td>.67</td>
</tr>
<tr>
<td>Time from diagnosis to trial treatment</td>
<td>&gt;18 mos</td>
<td>≤18 mos</td>
<td>2.77 (1.30-5.88)</td>
<td>.008</td>
</tr>
<tr>
<td>Treatment</td>
<td>Gemcitabine + nab-paclitaxel</td>
<td>Gemcitabine + nab-paclitaxel + NPC-1C</td>
<td>1.27 (0.65-2.47)</td>
<td>.48</td>
</tr>
</tbody>
</table>

SI conversion factor: To convert albumin levels to g/L, multiply by 10.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; IU/mL, International Unit/milliliter; g/dL, grams/deciliter.
nab-paclitaxel did not improve OS, PFS, and ORR over gemcitabine plus nab-paclitaxel alone. These disappointing results highlight the challenges of using therapeutics reliant on ADCC in tumors with an immunosuppressive microenvironment, such as PDAC.\textsuperscript{34,35}

Although many patients receive second-line gemcitabine plus nab-paclitaxel in routine clinical practice, few prospective studies have investigated second-line gemcitabine plus nab-paclitaxel after disease progression on FOLFIRINOX.\textsuperscript{36,37} This trial establishes important efficacy benchmarks for gemcitabine plus nab-paclitaxel as a second-line therapy for PDAC. The median OS for patients receiving second-line gemcitabine plus nab-paclitaxel alone was 6.6 months (95% CI, 4.7-8.4 months), the median PFS was 2.7 months (95% CI, 1.9-4.1 months), and the ORR was 2.9% (95% CI, 0.4%-18.7%). In agreement with our study, the Trybeca-1 phase III trial demonstrated that patients with PDAC treated with second-line gemcitabine/nab-paclitaxel had a median OS of 6.9 months and median PFS of 3.5 months.\textsuperscript{38} Notably, survival outcomes with second-line gemcitabine plus nab-paclitaxel are similar to those with fluororuracil-based second-line regimens observed in phase III clinical trials with a median PFS of 2 to 3 months and median OS of 6 to 7 months.\textsuperscript{39-43} The consistently modest efficacy of second-line chemotherapy in PDAC, regardless of regimen, demonstrates how PDAC becomes increasingly resistant to cytotoxic chemotherapy. The diminishing returns from cytotoxic chemotherapy emphasize the urgent need to develop other therapeutic strategies such as targeted and/or immunotherapeutic approaches.\textsuperscript{44} Future efforts targeting cell surface antigens in PDAC, such as MUC5AC or other mucins, could consider leveraging the increased cytotoxicity observed with third-generation antibody drug conjugates.\textsuperscript{45,46} The favorable toxicity profile of NPC-1C suggests the feasibility of anti-MUC5AC antibody drug conjugates.

The limited efficacy of second-line gemcitabine plus nab-paclitaxel presents a substantial challenge to clinicians discussing prognosis with their patients and to investigators designing future trials of second-line gemcitabine plus nab-paclitaxel in PDAC. We sought to identify clinical and demographic factors associated with survival among for patients with PDAC receiving second-line gemcitabine plus nab-paclitaxel. Using an exploratory multivariate analysis, we observed that reduced performance status (ECOG of 1 vs 0), hypoalbuminemia, PDAC diagnosis less than or equal to 18 months before trial enrollment, lymphocyte-to-monocyte ratio less than 2.8, and elevated CA19-9 level greater than 2000 IU/mL were independently associated with increased risk of death, in agreement with prior findings.\textsuperscript{2,25,26,29,32,33,36,47-51} Strikingly, though, there was a significant survival difference dependent upon the number of risk factors: patients with PDAC with 3 or more...
risk factors had a median OS of 4.3 months (95% CI, 2.6-5.6 months), which was significantly less than those patients with 2 or fewer risk factors (8.0 months [95% CI, 6.0-12.0 months]) (P < .001).

A challenge in using gemcitabine plus nab-paclitaxel as a second-line therapy is that the dosing schedule of this regimen was developed for PDAC patients in the first-line setting. Unlike most patients treated with first-line gemcitabine plus nab-paclitaxel, patients receiving second-line gemcitabine plus nab-paclitaxel had received first-line FOLFIRINOX which causes multiple cumulative toxic effects including myelosuppression and neuropathy. Unsurprisingly, patients in our study required frequent modifications of the gemcitabine plus nab-paclitaxel regimen. The high frequency of dose and schedule modifications suggest that clinicians should expect to tailor the gemcitabine plus nab-paclitaxel regimen when it is used as second-line therapy. Additionally, it suggests that future investigations of second-line gemcitabine plus nab-paclitaxel should consider modified dosing schedules.

**Limitations**

There are some limitations that may affect generalizability of the efficacy benchmarks and dose modification patterns of this study. One challenge in generalizing these data to all patients with PDAC receiving second-line gemcitabine plus nab-paclitaxel is that the patients in this study were required to meet strict protocol eligibility and consequently may reflect a fitter population than that routinely seen in clinical practice. Hence, the survival benchmarks and dose modification patterns reported here may be different compared with routine clinical practice. In addition, it is important to emphasize that patients in this study had MUC5AC expressing tumors (at least 20% of cells with NPC-1C staining by immunohistochemistry). The effects of MUC5AC positivity on prognosis and sensitivity to gemcitabine plus nab-paclitaxel is unknown, potentially affecting generalizability of our findings to the full population of patients with advanced PDAC. It also should be noted that the multivariate analysis of clinical and demographic factors associated with OS was conducted post hoc. However, other investigators have observed similar results.2,25,26,28,32,42,49,51 Finally, although enrolling an additional 10 patients would have been unlikely to affect the outcomes, the trial closed early for futility, thus slightly reducing the statistical power of the outcome comparisons.

**Conclusions**

This randomized clinical trial found that the addition of NPC-1C to second-line gemcitabine plus nab-paclitaxel did not improve survival outcomes. Data from this study clearly demonstrated that frequent dosing and schedule modifications of gemcitabine plus nab-paclitaxel are needed when this regimen is used in the second-line setting for the treatment of advanced PDAC. This trial establishes efficacy benchmarks of second-line gemcitabine plus nab-paclitaxel and identifies features that may aid in the design of future clinical trials.
Effect of NPC-1C Administered With Second-Line Gemcitabine and Nab-Paclitaxel on Patients With PDAC

Drs Huffman and Cleary had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Morse, Zaki, Schlechter, Sanoff, Arlen.

Acquisition, analysis, or interpretation of data: Huffman, Basu Mallick, Horick, Wang-Gillam, Hosein, Morse, Beg, Murphy, Mavroukakis, Zaki, Schlechter, Sanoff, Manz, Wolpin, Lacy, Cleary.

Drafting of the manuscript: Huffman, Morse, Cleary.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Huffman, Horick, Hosein, Manz, Cleary.

Administrative, technical, or material support: Huffman, Wang-Gillam, Beg, Mavroukakis, Manz, Arlen, Cleary.

Supervision: Beg, Schlechter, Cleary.

Conflict of Interest Disclosures: Dr Beg receiving research funding to his institution from Bristol Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics MedImmune, Genentech, Immunesensor, and Toleron Pharmaceuticals; he also has received honoraria for consulting from Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, and Foundation Medicine. Dr Wang-Gillam reported current employment with Jacobio. Dr Morse reported receiving honoraria from Ipsen, Genentech, AstraZeneca, Daiichi-Sankyo, Eisai, Taiho, and Servier; he also receives research support from Merck, Ipsen, Amal Therapeutics, Bristol Myers Squibb, and AAA/Novartis. Dr Sanoff reported receiving research funding to her institution from AstraZeneca Pharm, F. Hoffmann-La Roche Ltd, Rgenix Inc, and Exelixis Inc and grants from Amgen, Pfizer, and BioMed Valley Discoveries. Dr Arlen had a patent for NPC-1C issued. Dr Manz reported receiving a Conquer Cancer award that was funded by Genentech. Dr Wolpin reported receiving research support from Celgene, Eli Lilly, Novartis, and Revolution Medicine; he has received honoraria for consulting from BioLineRx, Celgene, GRAIL, and Mirati Therapeutics. Dr Lacy reported receiving honoraria for consulting and advising from Equinox, TechSpert, KeyQuest, Ipsen, First World Group, Guidepoint, Genentech, ASCO (ASCO-SEP editor), Apitude Health, Novartis, Deciphera, Brass Tacks Health, Bionest Partners, FirstThought, Objective Focus, Merck, and Fletcher Spaght. Dr Cleary receives research funding to his institution from AbbVie, Merus, Roche, and Bristol Myers Squibb; he also receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences, and Apexigen; he also has received honoraria for being on the advisory boards of Syros Pharmaceuticals, Incyte, and Blueprint Medicines. No other disclosures were reported.

Funding/Support: This trial and analysis was funded by Precision Biologics, Stand Up To Cancer, and the Lustgarten Foundation. The work of Dr Cleary is supported by Stand Up To Cancer and the Lustgarten Foundation. The work was also supported by a grant from the National Institutes of Health (PSOCA127003).

Role of the Funder/Sponsor: The sponsor (Precision Biologics) reviewed the manuscript and approved it for submission; it had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data and preparation of the manuscript.

Data Sharing Statement: See Supplement 3.

Additional Contributions: The authors are extremely grateful to the patients who participated in this trial and their families who supported them through the study. The authors thank Robert J. Mayer, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, for critical reading of the manuscript. He was not compensated for this contribution.

REFERENCES:


SUPPLEMENT 1.
Trial Protocol

SUPPLEMENT 2.
eTable 1. NPC-1C Staining Score
eTable 2. Best Radiological Response According to RECIST Criteria
eTable 3. Frequency of Adverse Events by Grade That Were Possibly, Probably, or Definitely Related to Protocol Treatment
eTable 4. Grade 3 or 4 Adverse Events Possibly, Probably, or Definitely Associated with Protocol Treatment
eTable 5. Relative Treatment Dose Intensity (RTDI)
eTable 6. Chemotherapy Dose Reductions
eTable 7. Modifications of Chemotherapy Administration Schedule
eTable 8. Univariate Analysis of Prognostic Features Associated with Overall Survival
eFigure 1. CONSORT Diagram for Patient Disposition
eFigure 2. Subgroup Analysis of Demographic and Baseline Disease Characteristics in Relation to Overall Survival
eFigure 3. Overall Survival of Patients Based on Presence of Prognostic Factors

SUPPLEMENT 3.
Data Sharing Statement